Irving PM

ORCID: 0000-0003-0972-8148 · 2 papers in corpus

nonrandomized-trial 2024

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Inflammatory bowel diseases ·doi:10.1093/ibd/izae024

BackgroundMirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative col…

observational 2023

Positioning intestinal ultrasound in a UK tertiary centre: significant estimated clinical role and cost savings

Frontline gastroenterology ·doi:10.1136/flgastro-2022-102156

OBJECTIVE: Intestinal ultrasound (IUS) is an inexpensive, non-invasive method of diagnosing and monitoring inflammatory bowel disease (IBD). We aimed to establish the proportion of lower gastrointestinal endoscopies (LGIEs) and magnetic res…